BIODYNE CO., LTD – Trademark Portfolio

Entity Type: 99

BIODYNE CO., LTD holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 7 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 2 Nice Classification classes. Currently, 4 trademarks are registered and 2 are pending. Notable registered marks include CELLPREP, EARLYPAP, PATHPLORE, and PATHPLORER.

24-4, Achasan-ro 5-gil,

Seongdong-gu Seoul 04793

7 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

BIODYNE CO., LTD's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (7 filings)

Surgical, medical, dental and veterinary apparatus and instruments

9
Computers & Electronics (2 filings)

Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments

Frequently Asked Questions

How many trademarks does BIODYNE CO., LTD have?

BIODYNE CO., LTD has 7 U.S. trademarks filed with the USPTO. Of these, 4 registered, 2 pending, 1 abandoned.

What trademark classes does BIODYNE CO., LTD file in?

BIODYNE CO., LTD files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 9 (Computers & Electronics). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are BIODYNE CO., LTD's most well-known trademarks?

BIODYNE CO., LTD's registered trademark portfolio includes well-known marks such as CELLPREP, EARLYPAP, PATHPLORE, and PATHPLORER. These are among 4 currently registered trademarks in the portfolio.

What is BIODYNE CO., LTD's trademark registration success rate?

BIODYNE CO., LTD has a 80% trademark registration rate, with 4 out of 5 resolved applications resulting in successful registration. Currently, 2 applications are pending review.